---
title: "The AI imperative for life sciences"
source_url: "https://www-cdn.anthropic.com/files/4zrzovbb/website/4ab17c5effbd02ad2ad86c278de0e8455a693305.pdf"
category: "19-Reference"
fetched_at: "2026-08-25T06:49:38Z"
tags: ["news-research"]
---

The AI imperative for life sciences                     3
Step 1: Lay the foundation                              5
Step 2: Launch a pilot                                  9
Step 3: Scale impact                                   12
Building an AI-first enterprise: real-world examples   14
Your AI transformation starts today                    17
The vision: AI-first enterprises that reshape life     20
sciences


                                                            2
The AI imperative
for life sciences
                    3
The AI imperative for life sciences
Life sciences organizations are putting frontier AI into the hands of their           This guide covers what matters at each step. We’ll start by identifying high-impact
scientists and regulatory teams, and the early movers are seeing real gains in how    use cases across R&D, clinical development, regulatory affairs, and commercial
quickly they can work.                                                                functions. We’ll then walkthrough how to build business cases that win cross-
                                                                                      functional support while meeting compliance requirements. And we’ll share how
The appetite is there. Deloitte's 2026 State of AI in the Life Sciences and           teams at Bluenote, Biomni, FutureHouse, and Novo Nordisk put AI to work to
Healthcare Industry report found that 72 percent of healthcare and life sciences      drive better scientific and regulatory outcomes.
companies plan to deploy agentic AI in the next two years. But only 34 percent
feel highly prepared to adopt it, and just 28 percent feel ready to handle the risk   Let's dive in.
and governance that come with it.

That gap is no surprise. The stakes are higher in life sciences than almost
anywhere else: patient safety and scientific integrity depend on getting it right.
Data is fragmented across discovery, development, and regulatory functions.
Frameworks like GxP, 21 CFR Part 11, FDA guidance, and the EU AI Act demand
rigorous compliance, and scientists rightly question whether AI can meet the
rigor their work requires.

Working alongside our customers, Anthropic has developed a proven approach to
bringing AI to life sciences organizations built for the realities of regulated
science:
• Lay the foundation. Organizations begin by building a solid base: strategy,
  stakeholder alignment, and governance.
• Launch a pilot. Next, teams run carefully chosen pilots that show value quickly
  while building real expertise.
• Scale impact. Finally, successful pilots expand across the business through
  structured rollout programs and centers of excellence.


                                                                                                                                                                       4
Step 1: Lay the foundation
                             5
Step 1: Lay the foundation
Driving AI adoption across a life sciences organization starts with deliberate      Technology alone cannot drive adoption in science. People and scientific
groundwork. In this section we cover how to define your strategy around life        workflows have to evolve alongside it. Organizations that treat change
sciences use cases, build alignment among scientific, regulatory, and technical     management as an afterthought struggle with adoption, especially when
stakeholders, and establish governance that meets GxP, FDA, and EU AI Act           scientists see AI as adding work rather than removing it.
requirements.
                                                                                    Assemble your AI steering committee
Driving leadership and stakeholder alignment                                        Successful change management starts with a steering committee that represents
                                                                                    critical functions and holds real decision-making authority. Include a C-suite
Leaders need to understand both the opportunity, including 20 to 30 percent         sponsor who can clear organizational obstacles, functional leaders who
gains in productivity and large reductions in documentation time, and the           understand operational realities, technology executives who grasp
challenges, including upfront investment, regulatory complexity, data integration   implementation requirements, finance representatives who track ROI and
hurdles, and the need to keep scientific judgment at the center of every result.    budgets, and legal or compliance leaders who can set governance.

Build a coalition across stakeholders                                               Prioritize deep listening
In life sciences, stakeholder alignment means securing support from, among          The most successful AI rollouts begin with listening rather than technology
others:                                                                             evangelism. Where do your scientists lose time to manual assembly work? Which
• Executive leadership (CEO, CFO, COO) who control resources and set                workflows feel broken? What keeps regulatory teams compiling submissions late
  strategic priorities                                                              into the night?
• Scientific leadership (CSO, VP of R&D, Head of Computational Biology) who         Starting with these pain points rather than the technology builds trust and makes
  understand research realities and influence scientific teams                      sure your strategy addresses real needs. When scientists see that AI targets the
• Clinical and regulatory leadership (VP of Clinical Operations, Head of            problems that frustrate them daily, they become advocates rather than skeptics.
  Regulatory Affairs, Head of Clinical Data Management) who own the path to
  submission                                                                        Address scientific skepticism directly
• IT leadership (CIO, CISO) who manage technical infrastructure and security        Scientists, bioinformaticians, and regulatory specialists have seen plenty of tools
                                                                                    that promised to make their lives easier and instead added burden. That history
• Compliance and quality teams who ensure GxP and regulatory adherence
                                                                                    creates legitimate skepticism, and it deserves a direct response.
• Bench scientists, bioinformaticians, and regulatory specialists who will
  ultimately decide whether AI tools succeed or fail


                                                                                                                                                                          6
• Acknowledge past technology disappointments rather than ignoring them              • Validation appropriate to the system's risk, with documented evidence that it
• Commit to measuring actual impact on scientific workflows, not just technical        does what it's intended to do
  metrics                                                                            • Audit trails that are tamper-evident, attributable, and readily searchable,
• Give scientists clear ways to give feedback and shape the rollout                    showing who did what and when

• Commit to sunsetting applications that don't deliver                               • Data integrity that meets ALCOA+ principles so records stay attributable,
                                                                                       legible, contemporaneous, original, and accurate
• Make clear that AI enhances scientific judgment, it doesn't replace it
                                                                                     • Change control that documents and reviews modifications before they reach a
This honest engagement builds credibility. Scientists respect leaders who flag the     regulated environment
hard parts early instead of overpromising.
                                                                                     FDA oversight considerations
Develop AI implementation champions                                                  AI that meets the definition of a medical device, including software as a medical
Beyond the steering committee, identify and empower champions at every level.        device (SaMD), requires FDA clearance or approval before deployment. Even if
These are respected managers who influence their peers, technical experts who        your first applications don't qualify, plan your governance with future oversight in
understand both legacy systems and AI, early adopters who bring energy, and          mind. Key considerations include pre-market submission requirements, clinical
thoughtful skeptics whose questions surface real risks. Give champions extra         validation, labeling, post-market surveillance, adverse-event reporting, and
training, direct access to leadership, and recognition that makes their advocacy     managing modifications under a predetermined change control plan.
visible across the organization.
                                                                                     EU AI Act compliance
                                                                                     For organizations operating in Europe or serving European patients, the EU AI
Regulatory alignment
                                                                                     Act classifies certain life sciences AI systems as "high-risk," which triggers
Life sciences AI governance has to address frameworks that other industries          extensive requirements:
never encounter, so it’s important to build compliance into your architecture from
                                                                                     • Risk management systems with documented assessments and mitigations
day one. Retrofitting it after deployment is costly and sometimes impossible
                                                                                       across the system lifecycle
without rebuilding. Below are the governance frameworks most likely to apply to
life sciences organizations.                                                         • Data governance that keeps training and reference data relevant,
                                                                                       representative, and free from bias
GxP and 21 CFR Part 11                                                               • Technical documentation maintained throughout the lifecycle, covering
Software that supports regulated development and manufacturing must meet               design, data characteristics, testing, change logs, and instructions for use
Good Practice (GxP) expectations and, for electronic records and signatures, 21
                                                                                     • Human oversight built into the architecture so people can interpret outputs,
CFR Part 11. In practice that means validated systems, controlled changes, and
                                                                                       override them when needed, and are trained to do so
complete audit trails. Build for it from the start:
                                                                                     • Robustness, accuracy, and cybersecurity appropriate to high-risk systems,
                                                                                       with monitoring after deployment


                                                                                                                                                                        7
Data privacy in clinical research                                                       • The Responsible Scaling Policy, our voluntary framework for assessing and
When AI touches patient data in clinical trials or real-world evidence, privacy           mitigating catastrophic risks as model capabilities advance — structurally
frameworks may apply, including GDPR in Europe and HIPAA in the United                    similar to the biosafety levels that already govern lab work
States. Make sure you have appropriate agreements with vendors who access               • The Trust Center, where we publish certifications, sub-processors, and data-
protected data, encryption in transit and at rest, role-based access, and breach-         handling commitments, including the availability of HIPAA-eligible offerings to
notification procedures. Treat patient data minimization and purpose limitation           customers who execute a Business Associate Agreement
as design principles, not afterthoughts.
                                                                                        • The Transparency Hub, with enforcement data, legal request handling, and
                                                                                          detail on how we approach user safety
Establish an AI governance framework                                                    • Claude's Constitution, which details the principles that guide Claude's
With compliance frameworks in place, you're ready to establish governance that            behavior
puts them into practice. A good framework enables innovation while managing
risk through policies that balance protection with productivity. Key components
include:
• Access controls that determine who can use AI systems and what data they can
  reach, with role-based permissions aligned to responsibilities and data sensitivity
• Usage guidelines that clarify acceptable applications and explicitly prohibit
  problematic ones, such as putting confidential IP or patient data into public AI
  models or making consequential decisions without human review
• Quality standards that set review requirements and accuracy thresholds,
  defining when outputs need human verification and when they can proceed
• Compliance protocols that meet regulatory requirements across jurisdictions,
  from GDPR to FDA regulations and GxP standards

The earlier you prioritize governance, the more durable your AI program will be.
Governance is core to how Anthropic builds. We were one of the first AI
companies to earn ISO 42001 certification for responsible AI, and we publish the
policies, evaluations, and risk reports behind our models so customers can hold us
to them. Many life sciences customers have found these resources useful:


                                                                                                                                                                        8
Step 2: Launch a pilot
                         9
Step 2: Launch a pilot
Good pilots deliver quick wins while building capability. Choose projects carefully,    3. Clinical trial protocol analysis
show cross-functional potential, and learn rigorously from every experiment.            Reviewing trial protocols against regulatory guidance, eligibility criteria, and
                                                                                        endpoint definitions can take weeks and several specialist reviewers. Claude
Choosing your pilot projects                                                            ingests full protocols, cross-references against guidance, flags inconsistencies, and
                                                                                        produces structured summaries with cited protocol sections for reviewer validation.
AI adoption in life sciences starts with pilots aligned to both business objectives     Because a human validates every finding, it's a low-risk way to move faster.
and scientific priorities. The goal is to find where AI delivers the most value while
keeping risk to patient safety and compliance low.
                                                                                        Showcase cross-functional potential
Unlike industries where "move fast and break things" is acceptable, life sciences
                                                                                        Successful pilots create momentum, but momentum alone won't scale adoption.
demands a measured approach. Starting with lower-risk, high-value applications
                                                                                        Design pilots that reveal possibilities beyond their immediate scope. When
builds capability and trust before tackling more complex scientific decision
                                                                                        research sees success with literature synthesis, clinical teams start imagining
support. Here are three strong first projects.
                                                                                        documentation applications. When drug safety demonstrates adverse-event
                                                                                        pattern detection, regulatory affairs envisions faster submission preparation. This
1. Scientific documentation and regulatory report generation                            cross-pollination drives organic expansion beyond the initial plan.
Tools that turn research data, study protocols, and clinical findings into structured
documentation, from regulatory submissions to research reports, are an ideal first      To evangelize AI adoption and foster knowledge-sharing, structured
investment. Scientific writing is low-hanging fruit because it accelerates existing     opportunities for cross-functional learning, such as a monthly AI showcase where
workflows without altering scientific judgment, and it can start with a small team.     pilot teams present their work. These sessions should include live demonstrations
Done well, it reduces researcher burnout, returns time to actual science, and           in scientific or regulatory workflows, before-and-after comparisons of
shows quick ROI.                                                                        documentation time or analysis speed, and open discussion of the validation
                                                                                        approaches and safety considerations discovered along the way.
2. Research synthesis and literature review
Scientific knowledge doubles every few years, and staying current across                Aligning on clear success metrics
hundreds of papers by hand is impossible. Claude synthesizes findings across
large bodies of literature, drawing on PubMed, bioRxiv, and proprietary                 Before launching any pilot, set concrete success metrics that stakeholders
databases, and delivers cited, structured insights tied to a specific research          understand and accept. They typically span five dimensions:
question. The work stays assistive and fully reviewable, which keeps risk low.


                                                                                                                                                                           10
• Adoption metrics track how many people use the tools and how often,
  including daily active users, feature use, and session frequency across teams
• Efficiency measures document time saved and productivity gains, such as
  cutting report preparation from weeks to hours
• Quality metrics confirm outputs meet your standards through measures like
  accuracy in data extraction, error rates, and first-pass approval rates
• Scientific and regulatory impact tracks outcomes that matter, such as faster
  discovery timelines, improved trial recruitment and retention, earlier safety-
  signal detection, and higher-quality submissions
• Satisfaction scores capture the user experience through Net Promoter Scores,
  task difficulty ratings, and willingness to recommend the tool

Track these weekly to catch issues early, review monthly to spot trends, and
adjust based on data rather than assumptions. This builds accountability and
confidence in your AI program.


Conduct pilot post-mortems
Once a pilot concludes, the real learning begins. Look past the headline numbers
to the story behind them: the moments when users found unexpected value, the
friction that emerged in practice, and the workarounds teams invented when the
tool didn't quite fit their workflow. These anecdotes are often more informative
than the metrics.

On the technical side, probe system reliability, integration snags, data-quality
surprises, and infrastructure needs that only appeared under real conditions.
Understanding adoption takes detective work: why did some teams embrace the
tool while others quietly resisted, and what practical barriers got in the way?


                                                                                   11
Step 3: Scale impact
                       12
Step 3: Scale impact
Moving from successful pilots to organization-wide adoption takes structured          Establish centers of excellence
training that builds real capability, centers of excellence that include scientific
                                                                                      Create specialized teams, or centers of excellence, dedicated to sustaining and
domain experts, and governance that scales with adoption while protecting
                                                                                      expanding AI capability. They develop best practices across functions, provide
patient safety and compliance.
                                                                                      technical support and troubleshooting, and systematically test new use cases.

Turn pilots into a launchpad for AI upskilling                                        Structure them with clear accountability and cross-functional representation that
                                                                                      prevents siloed thinking. Include technical architects who understand integration
Scaling success requires building deep AI capability across every role, from the C-   and data flows, domain experts from each major function who translate scientific
suite to your bench scientists. Treat training not as compliance modules but as an    needs into AI opportunities, and data scientists who tune performance and spot
investment in your people's ability to deliver better science with less               emerging capabilities.
administrative drag.

Don't overlook experiential learning. Hackathons bring energy and
                                                                                         Pro-tip: Establish rotation programs that bring functional experts into the
experimentation that top-down training never achieves. When teams compete to
                                                                                         center for three to six month stints, building their expertise while keeping
solve real problems with AI, learning happens organically and enthusiasm builds.
                                                                                         the center connected to evolving scientific needs.
Consider peer learning and mentorship that pairs experienced users with
colleagues just starting out, through regular check-ins, shadowing in real
workflows, and problem-solving sessions. You can also create certification
programs that validate competency through real-world assessments rather than
multiple-choice tests.


   Pro-tip: Celebrate certified users in internal communications, give them
   priority support, and consider certification in promotion decisions.
   Nothing signals commitment like tying advancement to AI proficiency,
   and that mindset shift is exactly what builds capability that outlasts any
   single pilot.


                                                                                                                                                                        13
Building an AI-first enterprise:
real-world examples
                                   14
Building an AI-first enterprise: real-world examples
Moving from isolated pilots to AI-native operations means rethinking entire            • 800 times faster bioinformatics analysis, 35 minutes instead of three weeks
workflows around AI rather than bolting on point solutions. The most successful        • Cloning experiment designs validated as equivalent to a 5+ year expert in blind
programs share a pattern: a breakthrough in one function becomes the catalyst            testing
for adoption across the enterprise. From day one, Anthropic has been committed
to working with life sciences organizations to help them realize the potential of AI   • Claude connected to 150 tools, 59 databases, and 106 software packages
across their organization. In fact, earlier this year, we announced our partnership
with Bristol Myers Squibb to deploy Claude across the company's research,              Literature synthesis
clinical development, manufacturing, commercial, and corporate functions.              FutureHouse built specialized research agents on Claude to help scientists stay
                                                                                       current across a literature base that doubles every few years.
The examples below show how organizations use Claude across the value chain,
and how early wins create momentum for broader change.                                 The challenge: science outpacing scientists
                                                                                       Biomedical literature is growing faster than any researcher can track. Staying
                                                                                       current across relevant studies, synthesizing findings, and identifying novel
Research and discovery: from literature to lab                                         directions can take months — time that isn't being spent on the research itself.
Life sciences organizations see their biggest gains when they connect related
                                                                                       The solution: specialized agents for scientific discovery
workflows across discovery and development.
                                                                                       FutureHouse built four Claude-powered agents spanning literature search,
                                                                                       analysis, novelty assessment, and drug discovery. Rather than replacing
Bioinformatics
                                                                                       researchers, the agents compress the front end of the scientific process —
Biomni set out to remove the bottleneck that locks most scientists out of genomic      surfacing what's known, flagging what's new, and freeing scientists to focus on
insight: the deep programming expertise that bioinformatics pipelines usually          what's next.
require.
                                                                                       • Literature reviews completed in days instead of months
The challenge: specialist dependencies slowing science
                                                                                       • Four specialized agents covering the full research workflow, from literature
A bench scientist with a hypothesis often can't run a genomic analysis without a
                                                                                         search to drug discovery
bioinformatician, so the scientists who could be designing the next experiment
end up waiting for someone else to run the last one.
The solution: Claude as a bioinformatics agent
Biomni built on Claude to run validated bioinformatics pipelines and deliver
annotated, reproducible reports, with built-in biosafety controls and full
methodology documentation.

                                                                                                                                                                          15
Regulatory and clinical development: from data to                                     Clinical workflows: Bluenote
submission                                                                            Bluenote built AI agents that let life sciences researchers spend their time on
While discovery teams accelerate the front of the pipeline, regulatory and clinical   science, not paperwork.
development teams use Claude to clear the documentation work that stands              The challenge: documentation that consumes researchers
between a finished trial and patient access.                                          Bringing a new treatment to market demands as much paperwork as it does
                                                                                      research. Regulatory submissions, clinical trial reports, and quality validations are
Regulatory documentation: Novo Nordisk                                                essential — but they consume days or weeks of a researcher's time.
Novo Nordisk tackled the documentation bottleneck that delays treatments from
                                                                                      The solution: Claude-powered agents for clinical and regulatory workflows
reaching patients.
                                                                                      Bluenote builds AI agents that automate the documentation work woven
The challenge: documentation delays blocking patient access                           throughout clinical operations—regulatory submissions, study reports, validation
Each new treatment requires mountains of documentation: clinical study reports        protocols, compliance forms. Their agents process regulatory documents,
running hundreds of pages, technical device verification protocols, and patient       generate technical reports with proper citations, and handle complex multi-step
guides written in plain language. Producing a single clinical study report was a      workflows, all with robust guardrails, data traceability, and highlighted calls to
multi-month effort, with staff writers averaging only 2.3 reports a year. Each day    action for human experts to contribute additional context and review. Claude
of delay in bringing a medicine to market can cost up to 15 million dollars in        serves as the default model for scientific and technical documentation, chosen for
potential revenue, and patients keep waiting.                                         its citation capabilities and accuracy in a domain where every claim must trace
                                                                                      back to a source.
The solution: the NovoScribe documentation platform
Novo Nordisk built NovoScribe, a generative AI platform on Amazon Bedrock             • 50–75% faster regulatory document production
and MongoDB Atlas with Claude as the frontier intelligence, developed using           • 10x faster protocol analysis for scientists
Claude Code. It combines retrieval-augmented generation with expert-approved
                                                                                      • Multi-hundred-page scientific documents with tables, figures, and citations
text and case-specific variables to produce accurate, compliant documentation,
                                                                                        generated in minutes
starting with clinical study reports and expanding to device protocols and patient
materials.                                                                            • Compliance gaps flagged automatically against the latest regulatory guidelines
• 10+ weeks to 10 minutes for clinical study documentation
• 95 percent reduction in resources for device verification protocols, from entire
  departments to single users
• 50 percent fewer review cycles through improved clinical accuracy
• Complete study booklets produced in under one minute
• An 11-person team that stays agile while expanding capabilities


                                                                                                                                                                         16
Your AI transformation
starts today
                         17
Your AI transformation starts today
Successful adoption begins with an honest assessment of where you stand and a                  Life Sciences AI Adoption Index
clear view of the path forward.
                                                                                               Before your first pilots, evaluate your organization across the dimensions below to
                                                                                               find your starting point.

                                                                                                                                                                               Your
  Dimension                 Building foundation (1–2)                   Growing capability (3–4)                          Transformation ready (5–6)                           score

  Executive commitment      AI viewed as an IT or informatics project   C-suite interested, competing R&D priorities      CEO championing AI across drug development,
                                                                                                                          multi-year commitment


  Data infrastructure       Siloed lab, clinical, and manufacturing     Centralized data warehouse, basic governance      Modern platform, automated pipelines from bench
                            systems; manual data entry                  and lineage tracking                              to submission


  Technical capabilities    Legacy LIMS and ERP, limited cloud          Hybrid cloud, basic DevOps, some API              Cloud-native, strong engineering team, real-time
                            adoption                                    integrations                                      data access


  Regulatory and            Reactive, manual controls; AI outputs not   Established validation program, regular audits,   Proactive controls, automated audit trails, AI
  compliance readiness      audit-ready                                 basic 21 CFR Part 11 compliance                   outputs validated for submission


  Change management         Initiatives stall due to scientific         Mixed adoption; scientists using AI tools         Proven change management, high trust among
                            skepticism or IT friction                   inconsistently                                    researchers and compliance teams


  Cross-functional          R&D, regulatory, and manufacturing          Regular cross-functional meetings, shared goals   Integrated teams across discovery, clinical, CMC,
  collaboration             operate in silos                            emerging                                          and regulatory affairs


  AI and ML maturity        No AI experience beyond exploratory         Initial models in production (e.g., predictive    Multiple AI applications deployed across the
                            tools                                       analytics, image analysis)                        development lifecycle


  Validated data and IP     No formal data governance for AI inputs     Data classification in progress, basic access     Validated data sources, clear IP ownership, audit-
  governance                                                            controls                                          ready provenance


  Budget and resources      Project-based funding tied to individual    Annual AI budget established, dedicated           Multi-year investment secured, AI embedded in
                            studies                                     informatics team                                  portfolio planning


                                                                                                                                                                                       18
Scoring guide:                                                                        Days 31–60: Prove
• 30 to 48 points (high readiness): Launch a comprehensive program with               With scaffolding in place, move the pilot into real work and let the evidence
  multiple pilots across functions.                                                   accumulate.
• 16 to 29 points (moderate readiness): Begin with three to five strategic pilots     • Go live in real workflows. Run the pilot inside actual studies and submissions
  while addressing foundational gaps.                                                   rather than sandboxes, with human review on every output.
• 8 to 15 points (building readiness): Secure executive sponsorship and               • Track metrics weekly. Review adoption, efficiency, and quality numbers as
  establish governance before launching one or two narrow pilots.                       they come in so you catch friction while there's still time to fix it.
                                                                                      • Hold structured feedback sessions. Capture what users route around, what
Your first 90 days: a pilot roadmap                                                     surprises them, and what they'd protect if the tool disappeared tomorrow.

The three steps in this guide fit inside a single quarter. Ninety days gives you      • Build the validation record as you go. Collect audit trails, review evidence, and
enough time to lay the foundation, prove value with real users, and earn the            change documentation now rather than reconstructing it later.
mandate to scale, without compromising the rigor regulated science demands.
                                                                                      Days 61–90: Scale
Days 1–30: Start and scaffold                                                         The final month converts pilot results into an expansion mandate.
Spend the first month on groundwork. None of it produces output yet, but all of it    • Run the post-mortem. Look past the headline numbers to the workarounds,
determines whether the next sixty days hold up.                                         surprises, and adoption patterns described in Step 2.
• Convene your steering committee. Confirm the executive sponsor, agree on            • Take results to the steering committee. Present metrics against the baselines
  decision rights, and set a meeting cadence that keeps pace with your speed of         you set in month one, and secure budget and sponsorship for the next wave.
  execution.                                                                          • Stand up your center of excellence. Seed it with pilot champions and the
• Pick one or two pilots. Start with the lower-risk, high-value use cases from Step     validation practices you've already proven, so the second wave starts faster
  2, such as scientific documentation or literature review, and define exactly          than the first.
  which workflow each pilot lives in.                                                 • Choose the next use cases. Let cross-functional demand from your showcases
• Set success metrics before launch. Agree on the adoption, efficiency, quality,        guide the queue, and sunset anything that didn't earn its place.
  and satisfaction measures you'll track weekly, and capture a baseline so
  improvement is measurable.
• Put guardrails in writing. Document access controls, review requirements, and
  escalation paths so compliance and quality teams can sign off before the first
  user logs in.
• Recruit your first users and champions. Choose respected scientists and
  regulatory specialists, including a few thoughtful skeptics, and give them a
  direct line to the project team.


                                                                                                                                                                         19
The vision: AI-first enterprises
that reshape life sciences
                                   20
The vision: AI-first enterprises that reshape life
sciences
Six months from now, your organization could look different. Research teams              Ready to begin your AI transformation?
compress discovery timelines by months as AI agents synthesize decades of                Join organizations already putting Claude to work.
literature and surface novel targets. Regulatory teams prepare submissions in
                                                                                         • Contact Anthropic's Sales team to discuss your use cases and implementation
weeks instead of quarters, with assistants that understand CFR, ICH guidelines,
                                                                                           strategy
and global requirements. Clinical operations resolve protocol questions and
safety signals in near real time.                                                        • Learn about Claude for Life Sciences, trusted by organizations like Eli Lilly,
                                                                                           AbbVie, and Sanofi to accelerate scientific discovery
The deeper change goes beyond efficiency. AI-first life sciences organizations
                                                                                         • Access Claude through the Claude for Microsoft 365, Claude Cowork, and
bring therapies to patients faster, catch safety signals earlier, and draw out insight
                                                                                           Claude Code
buried in decades of clinical and real-world data. They free every scientist to
focus on discovery and every regulatory team to build stronger submissions.              • Review our enterprise documentation and safety guidelines at
                                                                                           docs.anthropic.com and the Trust Center
The question isn't whether AI will reshape life sciences. It's whether your
                                                                                         • Explore Claude Code to accelerate scientific and regulatory engineering
organization will lead that change or follow competitors who moved first.
                                                                                           workflows


                                                                                                                                                                            21
claude.ai
